Commenting on the findings from KEYNOTE-407 in metastatic squamous NSCLC and IMpower132 in metastatic non-squamous NSCLC studies presented at ESMO 2018 Congress, Dr. Silvia Novello explains that these trials show the activity of the combination therapy, chemotherapy plus immunotherapy regardless of PD-L1 status. In KEYNOTE-407, the results are positive in terms of response and overall survival, and quality of life is also improved. In IMpower132, some subgroups of patients showed a clear benefit from the combination therapy.Conclusion remarks: Dr. Novello believes that the future may be a new treatment approach not only based on chemotherapy alone or immunotherapy alone depending on PL-L1 expression, but combined chemotherapy plus immunotherapy.

Major Sponsors

AstraZeneca Bristol-Myers Squibb MSD Servier

Main Sponsors

Amgen Astellas Bayer Healthcare Boehringer Ingelheim Daiichi Sankyo ipsen Janssen Novartis Roche